JP2023510724A5 - - Google Patents
Info
- Publication number
- JP2023510724A5 JP2023510724A5 JP2022541649A JP2022541649A JP2023510724A5 JP 2023510724 A5 JP2023510724 A5 JP 2023510724A5 JP 2022541649 A JP2022541649 A JP 2022541649A JP 2022541649 A JP2022541649 A JP 2022541649A JP 2023510724 A5 JP2023510724 A5 JP 2023510724A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957780P | 2020-01-06 | 2020-01-06 | |
| US62/957,780 | 2020-01-06 | ||
| PCT/US2021/012364 WO2021142029A1 (en) | 2020-01-06 | 2021-01-06 | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510724A JP2023510724A (ja) | 2023-03-15 |
| JP2023510724A5 true JP2023510724A5 (https=) | 2024-01-15 |
| JPWO2021142029A5 JPWO2021142029A5 (https=) | 2024-01-15 |
Family
ID=74418544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541649A Pending JP2023510724A (ja) | 2020-01-06 | 2021-01-06 | アウリスタチン関連化合物、コンジュゲートアウリスタチン化合物、およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20230071763A1 (https=) |
| EP (2) | EP4087613A1 (https=) |
| JP (1) | JP2023510724A (https=) |
| KR (1) | KR20220122659A (https=) |
| CN (2) | CN114929286A (https=) |
| AU (1) | AU2021206218A1 (https=) |
| BR (1) | BR112022013223A2 (https=) |
| CA (1) | CA3163860A1 (https=) |
| CL (1) | CL2022001773A1 (https=) |
| CO (1) | CO2022010796A2 (https=) |
| EC (1) | ECSP22061054A (https=) |
| IL (1) | IL294456A (https=) |
| MX (1) | MX2022008381A (https=) |
| PE (1) | PE20221574A1 (https=) |
| PH (1) | PH12022551426A1 (https=) |
| WO (3) | WO2021142043A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230071763A1 (en) * | 2020-01-06 | 2023-03-09 | Cytomx Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| US20250333487A1 (en) | 2022-03-25 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| US20260042849A1 (en) | 2022-08-01 | 2026-02-12 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025131025A1 (en) * | 2023-12-21 | 2025-06-26 | Lanova Medicines Development Co., Ltd. | Conjugates of anti-slc34a2 antibody and uses thereof |
| WO2025199352A2 (en) * | 2024-03-20 | 2025-09-25 | Juno Therapeutics, Inc. | Antibodies specific for solute carrier family 34 member 2 (slc34a2) |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1610818A4 (en) * | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
| EP2265283B1 (en) * | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| KR102023496B1 (ko) * | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| US9517276B2 (en) * | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| WO2015038426A1 (en) * | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| MX2017010102A (es) * | 2015-02-15 | 2017-11-23 | Jiangsu Hengrui Medicine Co | Conjugado farmaco citotoxico-ligando, metodo de preparacion del mismo, y sus aplicaciones. |
| CA2979219A1 (en) * | 2015-03-10 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind psma |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| CN109310885B (zh) * | 2016-03-15 | 2022-05-31 | 梅尔莎纳医疗公司 | NaPi2b靶向抗体-药物缀合物及其使用方法 |
| CA3134344A1 (en) * | 2016-04-06 | 2017-10-12 | Alteogen, Inc. | Antibody-drug conjugate comprising modified antibody |
| WO2017212250A1 (en) * | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| EP3522933B1 (en) * | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| CN108101825B (zh) * | 2016-11-25 | 2022-02-22 | 迈威(上海)生物科技股份有限公司 | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
| EP3692060A1 (en) * | 2017-10-03 | 2020-08-12 | Merck Patent GmbH | Cysteine engineered antigen-binding molecules |
| CN110152014B (zh) * | 2018-02-13 | 2022-09-27 | 烟台市和元艾迪斯生物医药科技有限公司 | 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途 |
| US12059473B2 (en) * | 2018-03-29 | 2024-08-13 | Ambrx, Inc. | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates |
| US20230071763A1 (en) * | 2020-01-06 | 2023-03-09 | Cytomx Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
-
2021
- 2021-01-06 US US17/790,835 patent/US20230071763A1/en active Pending
- 2021-01-06 JP JP2022541649A patent/JP2023510724A/ja active Pending
- 2021-01-06 WO PCT/US2021/012383 patent/WO2021142043A1/en not_active Ceased
- 2021-01-06 MX MX2022008381A patent/MX2022008381A/es unknown
- 2021-01-06 WO PCT/US2021/012364 patent/WO2021142029A1/en not_active Ceased
- 2021-01-06 AU AU2021206218A patent/AU2021206218A1/en not_active Abandoned
- 2021-01-06 KR KR1020227023304A patent/KR20220122659A/ko not_active Ceased
- 2021-01-06 CN CN202180008260.1A patent/CN114929286A/zh active Pending
- 2021-01-06 EP EP21702787.9A patent/EP4087613A1/en not_active Withdrawn
- 2021-01-06 CA CA3163860A patent/CA3163860A1/en active Pending
- 2021-01-06 PE PE2022001386A patent/PE20221574A1/es unknown
- 2021-01-06 BR BR112022013223A patent/BR112022013223A2/pt not_active IP Right Cessation
- 2021-01-06 EP EP21702784.6A patent/EP4087855A1/en active Pending
- 2021-01-06 US US17/790,838 patent/US20230073692A1/en active Pending
- 2021-01-06 CN CN202180008396.2A patent/CN114981287A/zh active Pending
- 2021-01-06 US US17/790,842 patent/US20230059690A1/en not_active Abandoned
- 2021-01-06 IL IL294456A patent/IL294456A/en unknown
- 2021-01-06 WO PCT/US2021/012379 patent/WO2021142039A1/en not_active Ceased
- 2021-01-06 PH PH1/2022/551426A patent/PH12022551426A1/en unknown
-
2022
- 2022-06-29 CL CL2022001773A patent/CL2022001773A1/es unknown
- 2022-08-01 CO CONC2022/0010796A patent/CO2022010796A2/es unknown
- 2022-08-04 EC ECSENADI202261054A patent/ECSP22061054A/es unknown